Cronus launches first FDA-approved generic pimobendan chewable

Cronus Pharma has commercially launched pimobendan chewable tablets in the U.S., giving veterinarians a newly available generic option for a drug long central to canine congestive heart failure management. According to the company, shipments are available after June 9, 2026, and the product is the first FDA-approved bioequivalent generic to Vetmedin. (businesswire.com)

The regulatory piece actually came earlier. FDA announced in April 2024 that it had approved Pimomedin, Cronus’ generic pimobendan chewable tablet, for dogs with mild, moderate, or severe congestive heart failure due to clinical myxomatous mitral valve disease or dilated cardiomyopathy. That approval established the generic pathway, but the current development is the product’s U.S. market release, which is what makes the approval meaningful for day-to-day prescribing. (fda.gov)

The label closely tracks the reference product. FDA’s freedom of information summary shows the drug is approved in 1.25 mg, 2.5 mg, 5 mg, and 10 mg half-scored chewable tablets, with a recommended total daily dose of 0.23 mg/lb, or 0.5 mg/kg, divided into two doses given about 12 hours apart. The agency said Cronus demonstrated bioequivalence through an in vivo blood-level study in 40 healthy, fasted dogs using the 5 mg tablet, while the remaining strengths received biowaivers based on dissolution comparability. No serious adverse events were reported in that bioequivalence study. (animaldrugsatfda.fda.gov)

Cronus is also leaning into the access argument. Its announcement says the tablets will move through national and regional distributors, and its product page lists four NDCs tied to the four strengths. That matters because pimobendan is typically a chronic therapy, and any improvement in supply continuity, formulary flexibility, or price competition could affect adherence for pet parents managing dogs with MMVD or DCM over months to years. That broader affordability implication is an inference, but it is consistent with the role generic entry usually plays once a product is actually stocked and dispensed. (businesswire.com)

There was limited independent expert reaction immediately available in open web coverage, but the clinical importance of pimobendan is well established. FDA describes the generic as containing the same active ingredient, dosage form, and concentration as Vetmedin, which was first approved in 2007. FDA has also separately cautioned veterinarians to use approved pimobendan products rather than unapproved versions when an approved option exists, underscoring the agency’s broader push toward labeled, quality-assured formulations. (fda.gov)

Why it matters: For veterinarians, this is less about a new mechanism than about a new market dynamic. Pimobendan is a standard therapy in canine cardiology, so the arrival of a commercially available FDA-approved generic could give practices another tool to support compliance, especially in long-term heart failure management where refill burden and cost can shape whether a pet parent stays on protocol. It may also reduce reliance on compounded alternatives in cases where an FDA-approved chewable product can meet the patient’s needs. At the same time, clinics will still need to pay attention to tablet strength selection, half-tablet dosing, distributor availability, and how pharmacy substitutions are communicated to pet parents. (fda.gov)

What to watch: The next signals will likely be practical ones: whether major distributors and clinic pharmacies stock the product quickly, whether pricing creates meaningful separation from brand Vetmedin, and whether Cronus expands contracting or educational support around the launch. Longer term, uptake may depend on how comfortable veterinarians and pet parents are with switching stable cardiac patients to a newly marketed generic, even one FDA has already deemed bioequivalent. (businesswire.com)